February 3, 2012
According to consolidated company results for the April-December 2011 period released on February 2, 2012, Eisai’s sales of Aricept (donepezil), the company’s mainstay treatment for Alzheimer’s disease (AD), dropped 50% a year after its patent had expired in the US...read more